珠海都市网
您当前的位置 :首页 > 文传商讯 > 正文
PeDRA 2026: Nemolizumab Phase II Data Show Long-Term Symptom Relief for Children Aged 2 to 11 Years With Moderate-to-Severe Atopic Dermatitis
2026年10月15日 17:48:36来源:作者:
【摘要】 Patient-reported outcomes from a phase II study of nemolizumab in children aged 2 to 11 with moderate-to-severe atopic dermatitis show meaningful reductions in itch severity, better sleep and improved quality of life, maintained for a year1

Patient-reported outcomes from a phase II study of nemolizumab in children aged 2 to 11 with moderate-to-severe atopic dermatitis show meaningful reductions in itch severity, better sleep and improved quality of life, maintained for a year1
Currently, there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis, despite the high unmet need – the disease can significantly reduce quality of life for children and create burden on their families2-8
These findings expand on the clinical evidence base for nemolizumab, which has multiple global approvals for adult and pediatric patients 12 years of age and older with moderate-to-severe atopic dermatitis, and adults with prurigo nodularis9,10

ZUG, Switzerland--(BUSINESS WIRE)--Galderma (SIX: GALD), the pure-play dermatology category leader, today announced new phase II data showing that nemolizumab provided meaningful improvements in itch, sleep disturbance, and quality of life in children aged 2 to 11 years with moderate-to-severe atopic dermatitis, sustained through Week 52.1 The results will be presented at The Pediatric Dermatology Research Alliance (PeDRA) Annual Conference.

Up to 25% of children are affected by atopic dermatitis - the most common inflammatory skin disorder in this population - and around one-third of these children have moderate-to-severe disease.11,12 Atopic dermatitis creates a high burden for both the patients and their loved ones, with persistent itch and recurrent skin lesions often disrupting sleep, school, and social confidence.2-8 Despite the high prevalence and significant burden, treatment options are limited in the pediatric setting for those with moderate-to-severe disease.3

 

“The burden of atopic dermatitis on children and their families remains considerable, with symptoms affecting quality of life, emotional wellbeing and day-to-day functioning. There is a continued need for treatment options that can deliver meaningful benefits for patients with moderate-to-severe disease. The results seen in this phase II study of nemolizumab are promising, with sustained improvements in itch severity, sleep disturbance and quality of life observed for up to one year.”

 

LAWRENCE EICHENFIELD, M.D.

PROFESSOR OF DERMATOLOGY AND PEDIATRICS AT THE UNIVERSITY OF CALIFORNIA SAN DIEGO SCHOOL OF MEDICINE AND CHIEF OF PEDIATRIC DERMATOLOGY AT

RADY CHILDREN’S HOSPITAL SAN DIEGO, UNITED STATES

 

 

责任编辑: admin

看新闻,关注新闻

搜狐网友:蓅姩媣栺圊舂
评论:每当我找到了成功的钥匙,就有人把锁给换了。

其它网友:Sunny°刺眼
评论:不为人知的猥琐是闷骚,无伤大雅的猥琐是情调。

腾讯网友:吓得魂飞魄散
评论:命运是存在的,只不过有人不敢去相信,有人不屑去相信而已。

天猫网友:-旧时光 seven ||
评论:既来之则安之,有福不享是傻子。

网易网友:未曾狂热付出&
评论:昨天去市里参加放鸽子比赛,结果就我一个人去了。

本网网友:〃失之我命
评论:人不如己,尊重别人,己不如人,尊重自己。

猫扑网友:▲戏子  2/5,°
评论:别忘了孔雀开屏光鲜亮丽的背后却是P眼儿

淘宝网友:俄怎会放得下
评论:我的优点:勇于认错;缺点:坚决不改。

百度网友:解脱的诠释
评论:一个女人的品位,在于她身边站着一个怎样品位的男人。

天涯网友:为了她放弃她
评论:我是个特别的人,我是个平凡的人,所以我是个特别平凡的人

相关阅读
分享到:
版权和免责申明

珠海都市网所有文字、图片、视频、音频等资料均来自互联网,不代表本站赞同其观点,本站亦不为其版权负责。相关作品的原创性、文中陈述文字以及内容数据庞杂本站无法一一核实,如果您发现本网站上有侵犯您的合法权益的内容,请联系我们,本网站将立即予以删除!